Cost-Containment Policies in Public Pharmaceutical Spending in the EU

67 Pages Posted: 15 Oct 2012

See all articles by Giuseppe Carone

Giuseppe Carone

European Commission - DG ECFIN

Christoph Schwierz

European Commission -DG ECFIN

Ana Xavier

European Commission -DG ECFIN

Date Written: September 14, 2012

Abstract

This paper presents and evaluates pharmaceutical policies in the EU aimed at the rational use of medicines and at keeping pharmaceutical spending under control. Policy makers are growing more aware that by regulating pharmaceutical markets correctly, considerable savings can be achieved without compromising the quality of care. Specifically, the paper makes the case that, by following numerous best-practices in pharmaceutical sector regulations, the value for money of pharmaceutical consumption could be substantially increased. Appropriate regulations can be relevant for pricing, reimbursement, market entry and expenditure control, as well as specific policies targeted at the distribution chain, physicians and patients.

Keywords: rational use of medicines, generic substitution, public pharmaceutical expenditure, pharmaceutical policies, cost-containment, value for money, pharmaceutical sector regulations

JEL Classification: I11, I18

Suggested Citation

Carone, Giuseppe and Schwierz, Christoph and Xavier, Ana, Cost-Containment Policies in Public Pharmaceutical Spending in the EU (September 14, 2012). Available at SSRN: https://ssrn.com/abstract=2161803 or http://dx.doi.org/10.2139/ssrn.2161803

Giuseppe Carone (Contact Author)

European Commission - DG ECFIN ( email )

BU-1 04/175
Brussels, Bruxelles B-1049
Belgium

Christoph Schwierz

European Commission -DG ECFIN ( email )

BU-1 05/190
Brussels, Bruxelles B-1049
Belgium

Ana Xavier

European Commission -DG ECFIN ( email )

Rue de la Loi 200
Brussels, B-1049
Belgium

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
652
Abstract Views
3,223
rank
50,603
PlumX Metrics